Y.D. More Investments Ltd Raises Position in Cellebrite DI Ltd. $CLBT

Y.D. More Investments Ltd lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 76.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 441,579 shares of the company’s stock after acquiring an additional 191,020 shares during the quarter. Y.D. More Investments Ltd owned 0.18% of Cellebrite DI worth $7,065,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. acquired a new position in Cellebrite DI during the 1st quarter worth approximately $60,939,000. Invesco Ltd. raised its position in Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock worth $64,043,000 after acquiring an additional 1,811,757 shares in the last quarter. Phoenix Financial Ltd. lifted its holdings in Cellebrite DI by 153.5% in the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock valued at $32,232,000 after acquiring an additional 1,219,958 shares during the period. Royal Bank of Canada boosted its position in shares of Cellebrite DI by 11,705.0% during the 1st quarter. Royal Bank of Canada now owns 824,226 shares of the company’s stock worth $16,015,000 after purchasing an additional 817,244 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Cellebrite DI during the 1st quarter worth $15,031,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $18.45 on Friday. Cellebrite DI Ltd. has a fifty-two week low of $13.10 and a fifty-two week high of $26.30. The company has a market capitalization of $4.42 billion, a price-to-earnings ratio of -24.28, a PEG ratio of 3.16 and a beta of 1.28. The stock has a fifty day moving average of $17.81 and a two-hundred day moving average of $16.68.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $126.03 million for the quarter, compared to analyst estimates of $122.98 million. During the same period in the previous year, the business earned $0.14 EPS. The firm’s revenue was up 17.9% on a year-over-year basis. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

CLBT has been the topic of a number of research analyst reports. Bank of America boosted their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday. Lake Street Capital boosted their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC raised their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Weiss Ratings lowered Cellebrite DI from a “hold (c-)” rating to a “sell (d-)” rating in a report on Thursday. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.